Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PacBio Agrees To Pay $800M For Omniome To Add Complementary Short-Read Sequencing Platform

Executive Summary

Pacific Biosciences has agreed to pay $600m upfront in cash and stock and up $200m in additional milestone payments to acquire Omniome. PacBio also announced a new private placement of common stock to raise $300m.

You may also be interested in...



Veracyte Continues Cancer IVD Expansion By Acquiring HalioDx For $318M

The deal is Veracyte’s second major acquisition in cancer diagnostics in 2021 after agreeing to acquire Decipher Biosciences in March.

US Government Opposes Proposed Illumina/Grail Merger

Illumina announced plans to acquire Grail for about $8bn in September 2020, but the US FTC says the proposed acquisition will diminish innovation in the US market for multi-cancer testing.

Inspira Goes Public To Develop Its Alternative To Mechanical Ventilation

The Israeli company raised $16m to support its Augmented Respiration Technology, a novel approach for delivering oxygen directly into the venous system. The company expects to earn FDA clearance for first product by 2023.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel